CALYM invites you to their event

RedTalks S4e3: Towards Risk-Adapted and Biology-Informed Treatment Approaches in Follicular Lymphoma

About this event

CALYM Institute launches its RedTalks, a Series of scientific Webinars

RedTalks s4e3: Towards Risk-Adapted and Biology-Informed Treatment Approaches in Follicular Lymphoma

We are delighted to welcome Pr. Oliver Weigert (MD-PhD) Attending Physician in Hematology & Medical Oncology and Professor for Translational Lymphoma Research.

Pr. Oliver Weigert graduated from Medical School at the Technical University Munich (TUM) in 2002 and obtained a medical degree (Dr. med.) in 2004. He completed his residency and fellowship training in Internal Medicine at the Ludwig-Maximilians-University (LMU) Hospital. Pr. Weigert was board-certified in Internal Medicine in 2009 and in Hematology and Medical Oncology in 2015. From 2009 to 2012 he was funded by the German Research Foundation and joined Prof. David Weinstock’s Laboratory at the Dana-Farber Cancer Institute (Harvard Medical School) as a Postdoctoral Research Fellow, studying genetic resistance mechanisms in lymphoid malignancies and the molecular ontogeny in follicular lymphoma.

Currently, Pr. Weigert is a Senior Attending Physician in the Department of Hematology & Medical Oncology at the LMU Hospital, Munich, co-heading the clinical lymphoma program and was appointed Assistant Professor in 2019 and Full Professor (W2) for Translational Lymphoma Research in 2021. He co-heads the Laboratory for Experimental Leukemia and Lymphoma Research (ELLF) and the Core Facilities “Digital Molecular Barcoding” and “Patient-Derived Organoids” of the German Cancer Consortium. Furthermore, Pr. Weigert served as elected spokesperson of the Biological Research Working Group of the German Lymphoma Alliance (GLA) from 2017-2021 and has been a member of the GLA Board of Directors since 2021.

Pr. Weigert’s laboratory uses agnostic multiomics approaches optimized to comprehensively profile formalin-fixed/paraffin-embedded primary patient material, currently including > 1,000 follicular lymphoma biopsies from clinical trials. Major findings include the development and validation of the clinicogenetic risk models m7-FLIPI (Pastore et al., Lancet Oncology 2015) and POD24-PI (Jurinovic et al., Blood 2016). Furthermore, they use advanced in-vitro and in-vivo model systems for functional characterization of clinically relevant candidate alterations, e.g. in Cathepsin S (CTSS) and STAT6 (Bararia et al., Cell Reports 2020; Mentz et al., Leukemia 2022).

During his talk, Pr. Weigert will try to describe the evolution of biomarkers in follicular lymphoma (FL) and how he envision a deeper understanding of the underlying biology to drive biology-guided treatment decisions.

Last but not least, we are pleased to welcome great moderators: Pr. Karin TARTE, Director of the MicrOenvironment and B-cell: Immunopathology cell DIfferentiation and Cancer (MOBIDIC – UMR INSERM U1236 – Rennes FR) and Dr. Mark ROSCHEWSKI, Clinical Director, Lymphoid Malignancies Branch Center for Cancer Research, NCI, NIH (Bethesda MD, USA)

👉 More informations about CALYM on

Hosted by

  • Team member
    FB T
    Fayrouz Ben Amara

  • Team member
    Laila Dahbi CALYM

  • Guest speaker
    BN G
    Bertrand Nadel Director @ Calym

  • Guest speaker
    OW G
    Oliver Weigert

  • Team member
    LD T
    Laila Dahbi Project leader @ CALYM

  • Guest speaker
    MR G
    Mark Roschewski

  • Guest speaker
    Karin Tarte

  • Guest speaker
    LH G
    Laurie Herviou CALYM

  • Guest speaker
    Emmanuel Gomez General Manager @ CALYM